GlaxoSmithKline to Purchase ID Biomedical
7th Sep 2005, 22:14 GMT
GlaxoSmithKline said it has agreed to buy ID Biomedical maker of the Fluviral flu shot, for about $1.4 bln as it moves to position itself as a leading influenza-vaccine manufacturer.
Latest news from Operations-Related News from myHealthcareNews.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies